Biovie Inc.
BIVI Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.24
KIRA · Stoqly’s AI analyst, in plain words
- Biovie Inc. lost $22.1M in fiscal 2026.
Market cap
$9.0M
P/E
—
Revenue
—
Net income
−$22.1M
Free cash flow
—
Operating margin
—
Biovie Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$22.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Biovie Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Aug 13, 2026
- Legal name
- BIOVIE INC.
- CIK
- 0001580149
Biovie Inc. · BIVI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$26.1M | −$50.3M | −$32.1M | −$17.5M | −$22.1M |
| Diluted EPS | −$1.06 | −$15.47 | −$73.05 | −$12.12 | −$3.05 |
| Cash | |||||
| Cash from operations | −$19.0M | −$40.3M | −$27.9M | −$19.0M | −$19.0M |
| Share count change | 98.8% | −86.8% | −86.1% | 226.9% | 390.4% |
| Debt and strength | |||||
| Cash and short-term investments | $18.6M | $19.5M | $23.8M | $17.5M | $9.0M |
| Shareholders' equity | $3.7M | $15.3M | $15.5M | $19.0M | $10.3M |
| Current ratio | 4.5x | 2.3x | 2.6x | 9.1x | 3.6x |
| Interest coverage | −12.6x | −10.5x | −11.1x | −54.3x | −1,265.5x |
| Returns and quality | |||||
| Return on equity | −598.2% | −528.7% | −208.3% | −101.6% | −150.8% |
| Return on tangible equity | −1,060.9% | −350.0% | −223.7% | −94.9% | −222.4% |
| Altman Z'' | −44.8 | −32.1 | −46.3 | −45.4 | −89.1 |
Insiders bought, 12 months
$0.0M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biovie Inc. · BIVI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.24 a share, the company is worth $9.0M.
Source: SEC EDGAR XBRL filings (CIK 0001580149). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.